NCT00638118已完成4 期
A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Size of change in skin flares from baseline will be measured.
研究概览
简要总结
Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals and flares induced by seasonal allergen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 15 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects, 15 to 55 years of age, may participate.
- •Subjects with a history of seasonal allergic rhinitis (due to ragweed; oak, elm or maple; or grasses) for the previous 2 years.
- •Positive seasonal allergen skin prick tests (or duplicate seasonal allergen skin prick test) with a summation flare greater than or equal to 20 mm larger than diluent control, and summation wheal greater than or equal to 6 mm larger than diluent control at the screening visit 1 (see Appendix 17.1); the seasonal allergen testing that results in the greatest summation flare will be used for all subsequent seasonal allergen testing.
- •All female subjects must have a negative urine pregnancy test at the screening visit.
- •Female subjects who are sexually active will be expected to use one of the following birth control methods throughout the study.
- •Subjects must be within 15% of normal body weight for height or a BMI less than 29.9 (based on NHLBI guidelines).
- •Subjects willing and able to adhere to visit schedules and all study requirements.
- •All female subjects must have a negative urine pregnancy test at each treatment visit (Visit 2, 4, and 6).
- •Continues to meet all inclusion and exclusion criteria.
排除标准
- •Asthma that requires treatment with medication other than an inhaled, short-acting beta agonist.
- •Significant signs and symptoms of currently active allergic disease (SAR, perennial allergic rhinitis, episodic allergic rhinitis).
- •Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2 weeks prior to visit
- •Subjects who have dermatographism or other skin conditions which might interfere with the interpretation of the skin test results.
- •Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy.
- •Any excessive amounts of alcohol (no more than two drinks/day on average).
- •Any excessive use of caffeine (more than six cups of coffee per day or equivalent).
- •Any history of chronic alcohol or mood-altering drug abuse.
- •Any use of tobacco/nicotine products within 90 days of visit
- •Any disease state or surgery known to affect the gastrointestinal absorption of drugs.
- •Known hypersensitivity to the investigational product or to drugs with similar chemical properties.
- •Subjects who will be visiting a tanning salon during the study.
- •Subjects who will need to use artificial tanning products during the study.
- •Pregnancy.
- •Breast-feeding.
- •Regular treatment with other H1-receptor antagonists in the last year before study entry.
- •No person or child of a person directly associated with the administration of the study may participate as a study subject.
- •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.
- •Treatment with any investigational product in the last 30 days before study entry.
- •Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult.
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- •Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.
- •Use of any of the following drugs within the time indicated prior to the first dosing visit: Systemic or injected corticosteroids (including oral, parenteral, intravenous, rectal) 30 days; Nasal or inhaled or ocular corticosteroids 30 days; Nasal or inhaled ipratropium bromide (or atropine), inhaled nedocromil, or nasal, inhaled, or ophthalmic sodium cromolyn 14 days; Agents with antihistaminic/anticholinergic activity (e.g. antidepressants, antipsychotics) 14 days; Leukotriene pathway modifiers (Accolate, Singulair, Zyflo) 10 days; Ocular anti-allergy medications including lodoxamide (Alomide), olopatadine (Patanol), emedastine difumarate (Emadine), levocabastine (Livostin) 10 days; Non-steroidal anti-inflammatory ophthalmics including ketorolac (Acular), flurbiprofen (Ocufen), suprofen (Profenal), diclofenac (Voltaren) 10 days; Antihistamines including desloratadine (Clarinex), loratadine (Claritin) 10 days; Antihistamines including fexofenadine HCl (Allegra), cetirizine (Zyrtec), hydroxyzine, azelastine nasal spray (Astelin), clemastine 7 days; Other short-acting antihistamines such as chlorpheniramine or drugs with antihistaminic activity 3 days; OTC oral antihistamines, decongestants (includes pseudoephedrine and other decongestants), or antihistamines/decongestant combinations including all cold, cough, and sleep aids 3 days; OTC ophthalmic decongestant,antihistamine, or decongestant/antihistamine combinations 3 days; Other anticholinergic agents 3 days; Immunotherapy injection 1 day.
- •Other drugs should only be permitted if they are not expected to interfere with the ability of the subject to participate in the study.
- •Non-steroidal anti-inflammatory agents are not allowed for 2 days prior to each treatment visit day through 25 hours post-dose (low-dose cardiac prophylaxis is allowed).
- •Use of any medications or agents that are not specified above that may confound the interpretation of the results:
- •Caffeine within 6 hours prior to each visit (coffee, tea, cola, and sodas, including Mountain Dew and Surge)
- •Decaffeinated coffee, tea and colas within 6 hours of each visit
- •Alcohol within 24 hours prior to each study visit
- •Chocolate within 6 hours prior to each visit
- •Antacids within +/- minus2 hours of investigational product dosing.
结局指标
主要结局
Size of change in skin flares from baseline will be measured.
时间窗: Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)
次要结局
- Size of change in skin wheals from baseline will be measured.(Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by HistamineAllergic RhinitisNCT00637585Sanofi42
尚未招募
不适用
Bioequivalance study of Fexofenadine 180 mg TabletsIRCT20200513047423N6Sana Med24
已完成
4 期
Fexofenadine in Pruritic Skin DiseasePruritusNCT00261079Handok Inc.435
尚未招募
不适用
Comparison of Fluticasone Furoate and Fexofenadine hydrochloride as initial treatment for Japanese cedar pollinosis: single-center,randomized,parallel-group studyJapanese cedar pollinosisJPRN-UMIN000004930Kansai Medical University60
已完成
1 期
Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting ConditionsHealthyNCT01066754Dr. Reddy's Laboratories Limited44